Advertisement
Canada markets close in 3 hours 57 minutes
  • S&P/TSX

    21,848.38
    -163.34 (-0.74%)
     
  • S&P 500

    5,054.18
    -16.37 (-0.32%)
     
  • DOW

    38,372.00
    -131.69 (-0.34%)
     
  • CAD/USD

    0.7289
    -0.0031 (-0.43%)
     
  • CRUDE OIL

    82.84
    -0.52 (-0.62%)
     
  • Bitcoin CAD

    88,660.96
    -2,463.26 (-2.70%)
     
  • CMC Crypto 200

    1,397.82
    -26.28 (-1.85%)
     
  • GOLD FUTURES

    2,339.50
    -2.60 (-0.11%)
     
  • RUSSELL 2000

    1,985.93
    -16.71 (-0.83%)
     
  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     
  • NASDAQ

    15,662.65
    -33.99 (-0.22%)
     
  • VOLATILITY

    16.11
    +0.42 (+2.68%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6818
    -0.0018 (-0.26%)
     

Global Dermatology Partnering Deals Report 2014-2021: Analysis & Trends of Over 650 Deals

Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Global Dermatology Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

The Global Dermatology Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 650 dermatology deals entered into by the worlds leading healthcare companies.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dermatology deals.

The report presents financial deal terms values for Dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of dermatology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in dermatology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading dermatology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to dermatology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2014. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

Report scope

Global Dermatology Partnering 2014-2021 includes:

  • Trends in dermatology dealmaking in the biopharma industry since 2014

  • Access to headline, upfront, milestone and royalty data

  • Access to over 650 dermatology deal records

  • The leading dermatology deals by value since 2014

ADVERTISEMENT

In Global Dermatology Partnering 2014-2021, the available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy target

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are the sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Dermatology dealmaking
2.1. Introduction
2.2. Dermatology partnering over the years
2.3. Dermatology partnering by deal type
2.4. Dermatology partnering by industry sector
2.5. Dermatology partnering by stage of development
2.6. Dermatology partnering by technology type
2.7. Dermatology partnering by therapeutic indication

Chapter 3 - Financial deal terms for Dermatology partnering
3.1. Introduction
3.2. Disclosed financials terms for Dermatology partnering
3.3. Dermatology partnering headline values
3.4. Dermatology deal upfront payments
3.5. Dermatology deal milestone payments
3.6. Dermatology royalty rates

Chapter 4 - Leading Dermatology deals and dealmakers
4.1. Introduction
4.2. Most active in Dermatology partnering
4.3. List of most active dealmakers in Dermatology
4.4. Top Dermatology deals by value

Chapter 5 - Dermatology contract document directory
5.1. Introduction
5.2. Dermatology partnering deals where contract document available

Chapter 6 - Dermatology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Dermatology therapeutic target

Appendices
Appendix 1 - Directory of Dermatology deals by company A-Z 2014 to 2021
Appendix 2 - Directory of Dermatology deals by deal type 2014 to 2021
Appendix 3 - Directory of Dermatology deals by stage of development 2014 to 2021
Appendix 4 - Directory of Dermatology deals by technology type 2014 to 2021

For more information about this report visit https://www.researchandmarkets.com/r/2noubd

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900